跳至主要内容
临床试验/NCT01637545
NCT01637545终止4 期

Phase 4 Study of Nasea(R)/Ramosetron Inj.as Anti-emetics in the Patients Undergoing Facial Bone Fracture Operations

Seoul National University Hospital1 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2011年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
入组人数
49
试验地点
1
主要终点
incidence and severity of nausea and vomiting

研究概览

简要总结

Postoperative nausea and vomiting (PONV) is one of the most common and distressing complications after anaesthesia and surgery, and may lead to serious postoperative complications This prospective, randomized study designed to evaluate the best injection time to get the prophylactic anti-emetic efficacy of ramosetron, a newly developed 5-HT(3) antagonist in patients undergoing facial bone surgery.

详细描述

  1. Participants
  • 100 patients with undergoing facial bone surgery are going to be randomly allocated to one of the 3 groups
  1. Randomization
  • G1(n=33) - Ramosetron 0.3mg i.v. just before the beginning of the surgery
  • G2(n=33) - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room
  • G3(n=33) - No medication but regular antiemetics i.v. if the patient wants
  1. The primary endpoint
  • the incidence of nausea and vomiting for 24 h after surgery at 0-6h, 6-12 h and 12-24 h
  1. The secondary endpoints
  • the severity of nausea, need for rescue medication
  • patient satisfaction with efficacy

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Participant)

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient who sign informed consent form for the study
  • patient who are considered as surgical candidates with facial bones fracture

排除标准

  • Patient who have had nausea/vomiting episodes

研究组 & 干预措施

Preop. ramosetron 0.3mg i.v.

Active Comparator

G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery

干预措施: Ramosetron (Drug)

Postop. ramosetron 0.3mg i.v.

Active Comparator

G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room

干预措施: Ramosetron (Drug)

No Ramosetron

Active Comparator

G3 - No medication but regular antiemetics injection if the patient wants

干预措施: Ramosetron (Drug)

结局指标

主要结局

incidence and severity of nausea and vomiting

时间窗: for 24 h after surgery at 0-6h, 6-12 h and 12-24 h

次要结局

  • patient satisfaction with the effect(at 24 h after surgery)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Chan-Yeong Heo

Assistant Professor

Seoul National University Hospital

研究点 (1)

Loading locations...

相似试验